Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials

Breast Cancer Research and Treatment

Volumn 152, Issue 1, 2015, Pages

  Mazzarello, Sasha ^a   Hutton, Brian ^a   Ibrahim, Mohammed F K ^b   Jacobs, Carmel ^b   Shorr, Risa ^c   Smith, Stephanie ^a   Ng, Terry ^b   Clemons, Mark ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Intra vaginal estrogens; Topical estrogen; Topical moisturizers; Urogenital atrophy

Indexed keywords

ESTRADIOL; LACTIC ACID; LIDOCAINE; PLACEBO; POLYCARBOPHIL;

BREAST CANCER; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; FEMALE SEXUAL DISTRESS SCALE; GENITAL SYSTEM DISEASE ASSESSMENT; HORMONE RESPONSE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN IRRITATION; SYSTEMATIC REVIEW; UROGENITAL ATROPHY; UROGENITAL TRACT DISEASE; VAGINA DISCHARGE; VAGINA PAIN; VAGINA PH; VAGINAL BURNING SENSATION; VAGINAL DRYNESS; VAGINAL HEALTH INDEX; VAGINAL MATURATION INDEX; VISUAL ANALOG SCALE; VULVA PRURITUS; ATROPHY; BREAST TUMOR; COMPLICATION; DISEASE MANAGEMENT; FEMALE; FEMALE UROGENITAL DISEASES; META ANALYSIS; PATHOLOGY;

ATROPHY; BREAST NEOPLASMS; DISEASE MANAGEMENT; FEMALE; FEMALE UROGENITAL DISEASES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84931005451     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3434-z     Document Type: Review

References (23)

1. Sturdee DW, Panay N, International Menopause Society Writing Group (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13(6):509–522
2. Sinha A, Ewies AA (2013) Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric 16(3):305–312
3. Ganz PA, Rowland JH, Meyerowitz BE et al (1998) Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 152:396–411
4. Baumgart J, Nilsson K, Stavreus-Evers A et al (2011) Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol 204(1):26e1–26e7
5. Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816
6. Suckling J, Lethaby A, Kennedy R (2006) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 4:CD001500
7. Holmberg L, Anderson H (2004) HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet 363(9407):453–455
8. von Schoultz E, Rutgvist LE, Stockholm Breast Cancer Study Group (2005) Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 97(7):533–535
9. Fahlen M, Fornander T, Johansson H et al (2013) Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 49(1):52–59
10. Trinkaus M, Chin S, Wolfman W et al (2008) Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 13(3):222–231
11. Chin SN, Trinkaus M, Simmons C et al (2009) Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Clin Breast Cancer 9(2):108–117
12. Gainford MC, Simmons C, Nguyen H et al (2005) A practical guide to the management of menopausal symptoms in breast cancer patients. Support Care Cancer 13(8):573–578
13. Bachmann G (1995) Urogenital ageing: an old problem newly recognized. Maturitas 22:S1–S5
14. Hess R, Austin RM, Dillon S et al (2008) Vaginal maturation index self-sample collection in mid-life women: acceptability and correlation with physician-collected samples. Menopause 15:726–729
15. Fallowfield LJ, Leaity SK, Howell A et al (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55(2):189–199
16. Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:5928
17. Simmons CE, Kuchuk I, Freedman OC et al (2012) Are Estring(R) and Vagifem(R) equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy? Clin Oncol (R Coll Radiol) 24(8):128–129
18. Goetsch MF, Lim JY, Caughey AB (2014) A solution for dyspareunia in breast cancer survivors. Obstet Gynecol 123(5):1S
19. Loprinzi CL, Abu-Ghazaleh S, Sloan JA et al (1997) Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 15(3):969–973
20. Lee YK, Chung HH, Kim JW et al (2011) Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 117(4):922–927
21. Modelska K, Cummings S (2002) Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87(1):16–23
22. Kenemans P, Bundred NJ, Foidart JM et al (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 10(2):135–146
23. Sismondi P, Kimmings R, Kubista E et al (2011) Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients—data from LIBERATE trial. Maturitas 70(4):365–372